Using a microsimulation model, the authors compared four TB diagnostic strategies for HIV-negative adults with presumptive TB in order to evaluate the potential cost-effectiveness of strategies that incorporate Truenat, a molecular assay that rapidly detects TB and rifampicin-resistance. They projected life expectancy, costs, incremental cost-effectiveness ratios (ICERs), and 5-year budget impact of deploying Truenat POC in India's public sector. Used at the point-of-care in India, Truenat for TB diagnosis should improve linkage-to-care, increase life expectancy, and be cost-effective compared with smear microscopy or Xpert.
Lee DJ, Kumarasamy N, Resch et al. Rapid, Point-Of-Care Diagnosis of Tuberculosis with Novel Truenat Assay: Cost-Effectiveness Analysis for India's Public Sector. PLoS One. 2019;14(7):e0218890. doi:10.1371/journal.pone.0218890.eCollection 2019.